Enzymotec (ENZY) Tops Q3 EPS by 1c

Enzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $9.5 million versus the consensus estimate of $10.22 million.

Enzymotec sees FY2014 EPS of $0.36-$0.45, versus the consensus of $0.36. Enzymotec sees FY2014 revenue of $47-50 million, versus the consensus of $48.5 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Micron reports Q4 today: Why Lynx Equity sees massive upside
• CarMax (KMX) PT Raised to $62 at UBS Following 'Encouraging' Q2 Print
• Norwegian Cruise Line stock rises on upbeat Q3 forecast